In accompanying studies we serially captured patients' health‐related quality of life, anxiety and depression, dynamics of fetal hemoglobin (HbF) expression as a potential predictive biomarker for erythroid differentiation during hypomethylating treatment [4, 12] and serial CD38 expression on AML blasts, a known marker of ATRA‐induced upregulation and therapeutic target [13]. The gene discussed is CD38; the disease is acute myeloid leukemia.